Skimmianine-mediated TNF-α suppression may contribute to decreased inflammation and immune evasion, aligning with studies showing that TLR4 targeting decreases proliferation and cytokine secretion in breast cancer cells [37]. Here, TLR4 is linked to breast carcinoma.